Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On 1 October 2019, the University of Oxford and the University of British Columbia (UBC) signed a Memorandum of Understanding, committing to work together to develop a new generation of clinical research leaders who will transform the translation of novel therapies from laboratory to clinic.

None © Photo credit: Kai Jacobson
(Left to right) Dr Dermot Kelleher, Dean of the UBC Faculty of Medicine, and Sir Gordon Duff, Principal of St Hilda’s College Oxford

As part of this initiative, UBC has created the Sultan Karim Fellowships in Clinical Pharmacology, which will support up to four clinicians seeking further research training and education in Clinical Pharmacology. This follows the establishment in 2017 of the Climax Chair of Clinical Therapeutics and Fellowships at St Hilda’s College. The Sultan Karim Fellowships and the Climax Chair and Fellowships have all been created thanks to the vision of Professor John Climax, an early champion of the field of Clinical Pharmacology and Therapeutics.

Read more (St Hilda's College website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.